The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.
about
BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interactionPML regulates p53 stability by sequestering Mdm2 to the nucleolusDynamic regulation of p53 subnuclear localization and senescence by MORC3PML promotes MHC class II gene expression by stabilizing the class II transactivatorMutant p53 Drives Cancer by Subverting Multiple Tumor Suppression PathwaysThe function, regulation and therapeutic implications of the tumor suppressor protein, PMLMDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon?Therapeutic considerations for Mdm2: not just a one trick ponyTumor suppression by p53: making cells senescent.PML-mediated signaling and its role in cancer stem cells.Impact of the adenoviral E4 Orf3 protein on the activity and posttranslational modification of p53.The tumor suppressor PML specifically accumulates at RPA/Rad51-containing DNA damage repair foci but is nonessential for DNA damage-induced fibroblast senescence.Move or die: the fate of the Tax oncoprotein of HTLV-1.PML nuclear bodies and apoptosis.Post-translational modification of p53 in tumorigenesis.Interleukin 6 signaling regulates promyelocytic leukemia protein gene expression in human normal and cancer cells.PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.Targeting Mdmx to treat breast cancers with wild-type p53.PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.Ubiquitin-dependent degradation of p73 is inhibited by PML.Post-translational modifications of PML: consequences and implications.Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression.New Strategies to Direct Therapeutic Targeting of PML to Treat CancersLoss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.The MDM2-p53 pathway revisitedGenetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signalingPML3 Orchestrates the Nuclear Dynamics and Function of TIP60New insights into the role of PML in tumour suppression.Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.Nucleophosmin blocks mitochondrial localization of p53 and apoptosis.Regulation of apoptosis by PML and the PML-NBs.Regulation of p53--insights into a complex process.PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites.Role of the promyelocytic leukaemia protein in cell death regulation.Senescence regulation by the p53 protein familyIs PML a Tumor Suppressor?PML tumour suppression and beyond: therapeutic implications.MDM4 is a rational target for treating breast cancers with mutant p53.
P2860
Q24295121-292B699D-F4BC-441C-B696-891247E7657CQ24296743-6DDEDE09-305E-41A0-B900-B27EC5CD0FEEQ24298683-8FEB6E98-6E7F-440B-BF4F-3A16623D7E5CQ24299467-9BBAAEA3-5884-4FE1-AA82-BA1FC6ECA38FQ26767396-DC4B4F04-3E6D-4A91-AC74-F8CF72F4E5F6Q26779358-17973EA5-B69B-4E75-B15F-429E85682800Q28204856-A38D52EB-D8C2-42C7-8C10-2487C697D2CFQ28755220-7C8C6428-7628-49CD-BD8F-CA460BE2C63CQ30380490-D9C89EF5-B35D-410E-AF03-A7B9333C30C1Q33736728-09B08E78-A62A-4D68-A37B-4D3D6307FEE0Q34337626-B2A9AC96-DF54-4DF5-89C1-8BACFF77F0AAQ35111076-3CEC2DA5-F382-48D8-AFA9-B1882C6E93A1Q35116715-C05C80D9-B5CB-462B-B0E2-8D000A9B76DEQ35261367-74D28BD0-61BC-4A77-91DF-3D28F65858C3Q35743115-3AB8640E-DB68-430D-81C6-9AD54B6499CBQ35930703-F89E04FE-46D8-497F-B98E-21E1A671B1DBQ36137373-B70FF57B-C7FC-4F55-9C14-C83784729B2AQ36191698-7AAA5B59-5267-4CB2-BAA0-7C17F4C11701Q36293839-5F59D561-92FE-4E05-91AB-15537429762DQ36305932-9B9C342E-EAB0-4FDA-A821-343E65BAE1C5Q36399088-5FF1265B-CDD5-407B-ACD1-19CA9C930842Q36516772-963973A5-7DEA-450A-B8EE-901BB58A6A94Q36664989-E948ED7D-7A89-474E-86E1-397A31D2C283Q36850742-944438CD-D6E5-466F-BF69-EF20BC24A261Q37018237-2581741E-6AC3-4B55-A1D3-DF16388B833DQ37039474-9D285A8E-16F8-4F32-BCB2-7BA561579741Q37106139-674594EF-5BB6-4BE3-B867-CAA371750170Q37136820-DFA5E301-891E-4FE1-B862-6E1BA576EF6DQ37173760-A3E677C2-247C-4297-B111-EDA5D7A080EDQ37258978-0908C251-68F0-486F-B304-88E192065520Q37269134-5A63C8C0-CBE2-4B1E-99EE-AE2023434F15Q37302759-B491C2E1-CD00-4FF8-A616-DF6DCBE8F388Q37636014-6F819B7B-9990-4567-A4F8-77C603570385Q37717357-7392E843-6A9F-4AD7-816E-90EE082E2A19Q37862984-64A68844-A349-4004-B1EC-7EF11741F29EQ37975087-8616C033-7BCC-4B72-AC62-5DDB637075CFQ38072351-8DF0539C-97BA-480F-BBBD-D3EAEEDBD8ACQ38121090-751D0D2D-1B53-40E8-A0A3-AE0740BD06E7Q38189168-5CEF5BB5-2502-4D15-AF6E-5412C95B6497Q38720844-28FAB005-E5AD-4CCF-9EA1-5E6EF06A43D5
P2860
The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
The promyelocytic leukemia pro ...... ed inhibition and degradation.
@en
The promyelocytic leukemia pro ...... ed inhibition and degradation.
@nl
type
label
The promyelocytic leukemia pro ...... ed inhibition and degradation.
@en
The promyelocytic leukemia pro ...... ed inhibition and degradation.
@nl
prefLabel
The promyelocytic leukemia pro ...... ed inhibition and degradation.
@en
The promyelocytic leukemia pro ...... ed inhibition and degradation.
@nl
P2093
P2860
P356
P1476
The promyelocytic leukemia pro ...... ed inhibition and degradation.
@en
P2093
Igal Louria-Hayon
Osnat Alsheich
Ronit Vogt Sionov
Tamar Grossman
P2860
P304
33134-33141
P356
10.1074/JBC.M301264200
P407
P577
2003-06-16T00:00:00Z